(PharmaNewsWire.Com, February 15, 2019 ) According to the new market research report “Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021", published by MarketsandMarkets™, report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the vaccine adjuvants market along with the estimates and forecasts of the revenue and market share analysis.
The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016 at a CAGR of 10.5% from 2016 to 2021. The major factors driving the growth of this market are high prevalence of infectious and zoonotic diseases, increasing focus on immunization programs by various government bodies, and growing focus on improved and long-lasting immunization against existing and emerging diseases.
Based on applications, the global vaccine adjuvants market is segmented into research and commercial applications. Research applications are expected to account for the largest share of the market during the forecast period. Growth in this segment is driven by factors such as increasing need for better immunization for the increasing geriatric population and increasing government funding in research to meet the unmet needs for safe and effective vaccine adjuvants.
On the basis of application categories, the vaccine adjuvants market is segmented into human and veterinary adjuvants. Adjuvants for humans are expected to account for the largest share of the global vaccine adjuvants market in 2016 and are expected to grow at a higher CAGR in the application category segment.
The key players in the vaccine adjuvants market include Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
